Recombinant adeno-associated virus (rAAV)-mediated delivery of a mutant endostatin (P125A-endostatin) has been shown to inhibit blood vessel formation and ovarian carcinoma growth [90]. This evidence concerns the gene COL18A1 and ovarian carcinoma.